Identifying Tumor Epitopes Recognized by CD4+ T Cells
Author Information
Author(s): Kierstead L S, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon Y L, Slingluff C L Jr, Kirkwood J M, Storkus W J
Primary Institution: University of Pittsburgh School of Medicine
Hypothesis
Can we identify tumor epitopes recognized by tumor-reactive human CD4+ T cells?
Conclusion
The study identified multiple CD4+ T cell epitopes that may be used as vaccine components to enhance immune responses in melanoma patients.
Supporting Evidence
- The study identified two known and three novel CD4+ T cell epitopes.
- Elevated frequencies of Th1-type CD4+ T cells were found in disease-free HLA-DR4+ melanoma patients.
- Peptide-reactive CD4+ T cells recognized melanoma cell lines expressing the relevant antigen.
Takeaway
Researchers found specific parts of melanoma that help the immune system fight cancer, which could be used to create better vaccines.
Methodology
The study used an HLA-DR4/peptide binding algorithm combined with an IFN-γ ELISPOT assay to identify CD4+ T cell epitopes.
Participant Demographics
The study involved HLA-DR4+ melanoma patients and normal donors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website